This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclearmedicine, diagnostic radiology, and radiation oncology.
As nuclearmedicine therapies gain stature compared to nuclearmedicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
Telix Pharmaceuticals and the Brussels-based Oncidium foundation are highlighting results from the NOBLE Registry of TLX599-CDx (technetium-99m [Tc-99m] inhibitor of prostate-specific membrane antigen [iPSMA]), published in the European Journal of NuclearMedicine and Molecular Imaging Reports.
Evans, PhD, has been named the 2024 recipient of the Society of NuclearMedicine and Molecular Imaging (SNMMI) Sam Gambhir Trailblazer Award. He completed a postdoctoral fellowship in molecular imaging at Memorial Sloan Kettering Cancer Center. He will be honored at the SNMMI's annual meeting in Toronto.
The scanner also comes with True Enhance DL, an AI-based application that generates deep learning-based monochromatic-like images from a single-energy x-ray acquisition. GEHC also pointed to upgrades for its Revolution Apex scanner, including ECG-less Cardiac for acquiring cardiac images without the need for an ECG signal or trace.
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A.,
milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based
Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclearmedicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.
The study will also then help identify early response to immunotherapies, using sequential whole-body imaging to monitor CD8 changes over time, enabling physicians to switch patients who are not responding to alternative treatment options sooner. For more information: www.gehealthcare.com References: Shankar L.
is the only FDA approved FES PET imaging agent. Cerianna is indicated for use with PET imaging for the detection of ER+ lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. GE HealthCare’s Cerianna , available in the U.S., J Nucl Med. 2011;52(10):1541-1549 / Currin, et al. J Natl Compr Canc Netw.
Earlier in his career, he held operational responsibilities for facility management of isotope production with Regional NuclearPharmaceuticals (now Cardinal Health). Mr. Vinyard, who has been with NorthStar since 2021, was previously Senior Director, Business Development, Therapeutic Technologies, for the Company. SPECT franchise.
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
produced, non-uranium based Mo-99 for use in diagnostic imaging. In parallel with these initiatives, NorthStar’s imaging portfolio continues to advance,” Mr. Merrick further added. Mr. Merrick concluded, “This is a very exciting and dynamic time for NorthStar and all those involved in nuclearmedicine.
Working with NorthStar, a proven leader in nuclearmedicine innovation and production, we believe that together we can ensure timely and efficient progression of our programs towards the clinic, and give patients broader access to potentially life-saving therapies."
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content